Treatment
Immunoglobulins clinical trials
We’re tracking 79 recruiting studies that include Immunoglobulins, each written for real people, not researchers, below.
Recruiting studies
- NCT05248659Enrolling by invitationPhase 2/Phase 3
Sibeprenlimab for IgA kidney disease after prior study
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Birmingham, AlabamaAges 18 years+ - NCT04881682RecruitingPhase 2
Testing blood-cleansing vs immunoglobulin for CIDP
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
Ulm, Baden-WurttembergAges 18 years+ - NCT04663204RecruitingPhase 2
Sparsentan study for IgA kidney disease in adults
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
Cambridge, EnglandAges 18 years+ - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT04924998Recruiting
Study for AL-CM treatment in adults at one hospital
This study is looking at a treatment approach for people diagnosed with AL-CM at a specific hospital. It may help researchers understand whether the treatment is safe and effective for patients like you.
Hangzhou, ZhejiangAges 18–80 - NCT04968899RecruitingPhase 3
IgG IV plus prednisone versus high-dose dexamethasone for ITP
This Phase 3 study compares two ways of treating immune thrombocytopenia (ITP) to raise blood platelet counts and reduce bleeding. It tests whether IgG given through a vein plus prednisone works better (or safer) than high-dose dexamethasone.
CréteilAges 18–80 - NCT07844668Enrolling by invitation
Gut health, diet, and quality of life in CVID
This study looks at the gut microbiome (the bacteria in your digestive system), diet, and quality of life in people with CVID, a condition that affects the immune system. It compares those who receive immunoglobulin therapy (antibody treatment) with those who do not, to see if there are differences that might help improve care.
Ninove, BelgieAges 18 years+ - NCT02735707RecruitingPhase 3
Adaptive trial for severe pneumonia care in intensive care
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
Jacksonville, FloridaAges 18 years+ - NCT05775042RecruitingPhase 2
CM338 for immunoglobulin A kidney disease
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
Beijing, Beijing MunicipalityAges 18–75 - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Newcastle, New South WalesAges 18 years+ - NCT06661603Recruiting
Yoga and meditation for medical students' health
This study looks at how doing yoga and meditation might affect stress hormones, immune markers, and health in medical students. If you are a medical student at the University of Pecs, you may be able to join and learn how these practices can help your well-being.
Pécs, PécsAges 18–40 - NCT07561125RecruitingPhase 2
IVIG for lung disease in very preterm infants
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
ShanghaiAges 1 day–2 months - NCT07541287RecruitingPhase 2
JADE101 for IgA Nephropathy Kidney Disease
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Chula Vista, CaliforniaAges 18–60 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07522099RecruitingPhase 2
Study of ADARx Treatment for Kidney Disease in Chinese Adults
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
Shenzhen, GuangdongAges 18 years+ - NCT07509151RecruitingPhase 3
Surovatamig after first treatment for CLL or SLL
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
La Jolla, CaliforniaAges 18–18 - NCT06183645Recruiting
Predicting CIDP decline during IVIg treatment changes
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
Liège, LiègeAges 18–99 - NCT07375758RecruitingPhase 1/Phase 2
Testing MIL116 in healthy people and those with IgA Nephropathy
This study tests a new drug called MIL116 for IgA Nephropathy. First, healthy volunteers will test the drug's safety, then people with IgA Nephropathy will see if it can help reduce protein in their urine.
BeijingAges 18 years+ - NCT07328711RecruitingEarly Phase 1
Immunotherapy for chronic hepatitis B after HBsAg loss
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Beijing, Beijing MunicipalityAges 18–60 - NCT07273903Recruiting
Tracking CIDP treatment with a smartwatch
This trial tests whether a smartwatch can help monitor how well subcutaneous immunoglobulin (fSCIG) works for people with CIDP who recently switched from IVIG or plan to switch. It aims to make treatment tracking easier and more convenient.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07232459Recruiting
PET imaging for amyloidosis in the heart
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
Hefei, AnhuiAges 18 years+ - NCT06740526RecruitingPhase 2
A trial of sibeprenlimab for IgA nephropathy kidney tissue
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
Denver, ColoradoAges 16 years+ - NCT07190196RecruitingPhase 3
Study of Rilzabrutinib for IgG4-related disease
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
Fontana, CaliforniaAges 18 years+ - NCT07187531RecruitingPhase 2
Testing a new drug to preserve insulin production in type 1 diabetes
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
San Francisco, CaliforniaAges 5–40
Common questions
- Are there clinical trials studying Immunoglobulins?
- Yes. Clin2 currently lists 79 recruiting studies that include Immunoglobulins, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Immunoglobulins trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Immunoglobulins an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Immunoglobulins or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.